Related Experiment Video
Updated: Feb 24, 2026

Patient-Derived Tumor Explants As a "Live" Preclinical Platform for Predicting Drug Resistance in Patients
Published on: February 7, 2021
Testing many treatments within a single protocol over 10 years at MRC Clinical Trials Unit at UCL: Multi-arm,
Mahesh Kb Parmar1, Matthew R Sydes1, Fay H Cafferty1
11 MRC Clinical Trials Unit at UCL, University College London, London, UK.
Abstract:
There is real need to change how we do some of our clinical trials, as currently the testing and development process is too slow, too costly and too failure-prone often we find that a new treatment is no better than the current standard. Much of the focus on the development and testing pathway has been in improving the design of phase I and II trials. In this article, we present examples of new methods for improving the design of phase III trials (and the necessary lead up to them) as they are the most time-consuming and expensive part of the pathway. Key to all these methods is the aim to test many treatments and/or pose many therapeutic questions within one protocol.
More Related Videos
09:16Mixed Primary Cultures of Murine Small Intestine Intended for the Study of Gut Hormone Secretion and Live Cell Imaging of Enteroendocrine Cells
Published on: April 20, 2017
10:10Long-term Culture of Human Breast Cancer Specimens and Their Analysis Using Optical Projection Tomography
Published on: July 29, 2011